Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference

Rhea-AI Summary

Fractyl Health, Inc. (Nasdaq: GUTS), a metabolic therapeutics company focusing on new approaches to treat obesity and Type 2 Diabetes, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference. The company's Co-founder and CEO, Harith Rajagopalan, M.D., Ph.D., will engage in a fireside chat on Tuesday, October 1, 2024, at 9:00 a.m. EDT.

Interested parties can register in advance for the presentation webcast. Following the live session, a replay will be available on the Events page of the Investors section on Fractyl Health's website at https://ir.fractyl.com/. This presentation offers an opportunity for investors and interested individuals to gain insights into Fractyl Health's innovative approaches in metabolic therapeutics.

News Market Reaction – GUTS

-1.77%

-1.77% Session move

In the trading session that priced this news, GUTS declined 1.77%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGTON, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D)), today announced that Harith Rajagopalan, M.D., Ph.D., Co-founder and Chief Executive Officer of Fractyl Health, will participate in a fireside chat at Chardan’s 8^th Annual Genetic Medicines Conference on Tuesday, October 1, 2024, at 9:00 a.m. EDT.

To register in advance for the presentation webcast, sign up here.

A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.fractyl.com/.

About Fractyl Health

Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com.

Contacts 

Corporate Contact 
Lisa Davidson, Chief Financial Officer 
ir@fractyl.com, 781.902.8800

Media Contact 
Jessica Cotrone, Corporate Communications
jcotrone@fractyl.com, 978.760.5622

Investor Contact
Stephen Jasper, Gilmartin Group
stephen@gilmartinir.com, 619.949.3681

FAQ

When is Fractyl Health (GUTS) presenting at Chardan's Genetic Medicines Conference?

Fractyl Health (GUTS) is presenting at Chardan's 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024, at 9:00 a.m. EDT.

Who will be representing Fractyl Health (GUTS) at the Chardan conference?

Harith Rajagopalan, M.D., Ph.D., Co-founder and Chief Executive Officer of Fractyl Health, will represent the company in a fireside chat at the conference.

How can I watch Fractyl Health's (GUTS) presentation at the Chardan conference?

You can register in advance for the presentation webcast. A replay will also be available on the Events page of the Investors section on Fractyl Health's website at https://ir.fractyl.com/ after the live session.

What is the focus of Fractyl Health's (GUTS) research?

Fractyl Health (GUTS) is a metabolic therapeutics company focused on pioneering new approaches to treat root causes of obesity and Type 2 Diabetes (T2D).